CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The AML-VACCiN project focuses on developing a dendritic cell vaccine to eliminate minimal residual disease in acute myeloid leukaemia patients. The aim is to enhance treatment outcomes and reduce relapse rates through innovative immunotherapy.
Eradicating minimal residual disease (MRD) in patients with acute myeloid leukaemia (AML) is an area of high unmet medical need. AML is a deadly rare disease that affects both children and adults.
Approximately 45% of younger AML patients who are treated will be cured, and in older patients (>60 years of age), 85% will relapse and die within 2 years.Immunotherapy has great potential for treating MRD and dendritic cell (DC) therapy is at the forefront of immunotherapy.
The AML-VACCiN consortium t…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, IDAR OBERSTEIN
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Germany, TUEBINGEN
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Norway, Bergen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Netherlands, LEIDEN
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
